Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

JOUNCE THERAPEUTICS, INC.

(JNCE)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news
Communiqués de presse de la société JOUNCE THERAPEUTICS, INC.
09/15JOUNCE THERAPEUTICS : Departures of Directors or Certain Officers; Election of Directors; ..
PU
09/15JOUNCE THERAPEUTICS, INC. : Change in Directors or Principal Officers (form 8-K)
AQ
09/15Jounce Therapeutics Appoints Jigar Raythatha to its Board of Directors
GL
09/02Jounce Therapeutics to Present at Upcoming Investor Conferences in September
GL
08/05JOUNCE THERAPEUTICS : Management's Discussion and Analysis of Financial Condition and Resu..
AQ
08/05Jounce Therapeutics Reports Second Quarter 2021 Financial Results
GL
08/05JOUNCE THERAPEUTICS, INC. : Results of Operations and Financial Condition, Financial State..
AQ
07/29Jounce Therapeutics to Announce Second Quarter 2021 Financial Results and Host a Confer..
GL
07/07JOUNCE THERAPEUTICS : to Participate in William Blair's Biotech Focus Conference
AQ
06/23JOUNCE THERAPEUTICS, INC. : Submission of Matters to a Vote of Security Holders (form 8-K)
AQ
06/23Jounce Therapeutics Provides Update on INNATE Study and Discovery Pipeline Expansion, a..
GL
06/16Jounce Therapeutics to Host Virtual R&D Day on June 23, 2021
GL
06/15GILEAD SCIENCES : Jounce Therapeutics Achieves First Milestone in Exclusive License Agreem..
AQ
06/14Jounce Therapeutics to Participate in Fireside Chat at the Raymond James Human Health I..
GL
06/04Jounce Therapeutics Presents Trial in Progress Posters on the INNATE and SELECT Clinica..
GL
05/04JOUNCE THERAPEUTICS : Management's Discussion and Analysis of Financial Condition and Resu..
AQ
05/04JOUNCE THERAPEUTICS : Enrollment on track in both the Phase 1 INNATE trial of JTX-8064 (LI..
PU
05/04JOUNCE THERAPEUTICS, INC. : Results of Operations and Financial Condition, Financial State..
AQ
05/04Jounce Therapeutics Reports First Quarter 2021 Financial Results
GL
04/28Jounce Therapeutics to Present Trial in Progress Posters on the Phase 1 INNATE and the ..
GL
04/27Jounce Therapeutics to Announce First Quarter 2021 Financial Results and Host Conferenc..
GL
04/12Jounce Therapeutics Appoints Dmitri Wiederschain, Ph.D., as Chief Scientific Officer
GL
04/10Jounce Therapeutics Presents Preclinical Data from JTX-8064/LILRB2 Program at the 2021 ..
GL
03/12Jounce Therapeutics Announces Closing of Public Offering and Full Exercise of Over-Allo..
GL
03/11JOUNCE THERAPEUTICS : to Present Preclinical Data from JTX-8064 Program at the 2021 Americ..
AQ
03/10JOUNCE THERAPEUTICS, INC. : Entry into a Material Definitive Agreement (form 8-K)
AQ
03/10Jounce Therapeutics to Present Preclinical Data from JTX-8064 Program at the 2021 Ameri..
GL
03/09Jounce Therapeutics Announces Pricing of $56.25 Million Public Offering of Common Stock
GL
03/09Jounce Therapeutics Announces Proposed Offering of Common Stock
GL
02/25JOUNCE THERAPEUTICS : Management's Discussion and Analysis of Financial Condition and Resu..
AQ
02/25JOUNCE THERAPEUTICS, INC. : Results of Operations and Financial Condition, Financial State..
AQ
02/25Jounce Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results
GL
02/23Jounce Therapeutics to Present at Upcoming Investor Conferences in March
GL
02/18Jounce Therapeutics to Announce Fourth Quarter and Full Year 2020 Financial Results and..
GL
02/15JOUNCE THERAPEUTICS : Appoints Luisa Salter-Cid, Ph.D., to its Board of Directors
AQ
02/12JOUNCE THERAPEUTICS, INC. : Change in Directors or Principal Officers (form 8-K)
AQ
02/12Jounce Therapeutics Appoints Luisa Salter-Cid, Ph.D., to its Board of Directors
GL
01/14JOUNCE THERAPEUTICS : Announces Initiation of Phase 1 INNATE Study of JTX-8064 Monotherapy..
AQ
01/13Jounce Therapeutics Announces Initiation of Phase 1 INNATE Study of JTX-8064 (LILRB2/IL..
GL
01/11JOUNCE THERAPEUTICS : to Present at Upcoming Investor Conferences in January
AQ
01/11JOUNCE THERAPEUTICS, INC. : Results of Operations and Financial Condition, Regulation FD D..
AQ
01/08Jounce Therapeutics to Present at Upcoming Investor Conferences in January
GL
2020JOUNCE THERAPEUTICS : Added to NASDAQ Biotechnology Index
AQ
2020JOUNCE THERAPEUTICS : to Participate in a Fireside Chat at the Piper Sandler 32nd Annual V..
AQ
2020Jounce Therapeutics to Participate in a Fireside Chat at the Piper Sandler 32nd Annual ..
GL
2020JOUNCE THERAPEUTICS : to Participate in a Fireside Chat at the Piper Sandler 32nd Annual V..
AQ
2020JOUNCE THERAPEUTICS : Receives Study May Proceed Letter from US FDA to Initiate Phase 1 Cl..
AQ
2020JOUNCE THERAPEUTICS : Receives Study May Proceed Letter from US FDA to Initiate Phase 1 Cl..
AQ
2020Jounce Therapeutics Receives Study May Proceed Letter from US FDA to Initiate Phase 1 C..
GL
2020JOUNCE THERAPEUTICS : Presents Preclinical Data from JTX-8064 Program at the Society for I..
AQ
2020Jounce Therapeutics Presents Preclinical Data from JTX-8064 Program at the Society for ..
GL
2020JOUNCE THERAPEUTICS : to Participate in a Virtual Fireside Chat at Cowen 2020 IO Next Summ..
AQ
2020JOUNCE THERAPEUTICS : Reports Third Quarter 2020 Financial Results
AQ
2020JOUNCE THERAPEUTICS : to Participate in a Virtual Fireside Chat at Cowen 2020 IO Next Summ..
AQ
2020Jounce Therapeutics to Participate in a Virtual Fireside Chat at Cowen 2020 IO Next Sum..
GL
2020JOUNCE THERAPEUTICS : Management's Discussion and Analysis of Financial Condition and Resu..
AQ
2020JOUNCE THERAPEUTICS : Reports Third Quarter 2020 Financial Results
AQ
2020JOUNCE THERAPEUTICS, INC. : Results of Operations and Financial Condition, Financial State..
AQ
2020Jounce Therapeutics Reports Third Quarter 2020 Financial Results
GL
2020JOUNCE THERAPEUTICS : Announces Update on Vopratelimab Program
AQ
2020JOUNCE THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
2020JOUNCE THERAPEUTICS : Announces Update on Vopratelimab Program
AQ
2020Jounce Therapeutics Announces Update on Vopratelimab Program
GL
2020JOUNCE THERAPEUTICS : to Announce Third Quarter 2020 Financial Results and Host Conference..
AQ
2020JOUNCE THERAPEUTICS : to Announce Third Quarter 2020 Financial Results and Host Conference..
AQ
2020Jounce Therapeutics to Announce Third Quarter 2020 Financial Results and Host Conferenc..
GL
2020Jounce Therapeutics to Participate in Upcoming Virtual Investor Conferences in Septembe..
GL
2020JOUNCE THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Unregistered Sale ..
AQ
2020Gilead Sciences and Jounce Therapeutics Announce Exclusive License Agreement for Novel ..
GL
2020JOUNCE THERAPEUTICS : Reports Second Quarter 2020 Financial Results
AQ
2020JOUNCE THERAPEUTICS : Management's Discussion and Analysis of Financial Condition and Resu..
AQ
2020JOUNCE THERAPEUTICS, INC. : Results of Operations and Financial Condition, Financial State..
AQ
2020Jounce Therapeutics Reports Second Quarter 2020 Financial Results
GL
2020Jounce Therapeutics to Participate in a Fireside Chat at BTIG Virtual Biotechnology Con..
GL
2020JOUNCE THERAPEUTICS : to Announce Second Quarter 2020 Financial Results and Host Conferenc..
AQ
1  2  3Next
Upcoming event on JOUNCE THERAPEUTICS, INC.